TuHURA Biosciences Financials

HURA

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

Financial Health Signals

Piotroski F-Score Neutral

4/9

TuHURA Biosciences passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.68x

For every $1 of reported earnings, TuHURA Biosciences generates $0.68 in operating cash flow (-$14.7M OCF vs -$21.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

This page shows TuHURA Biosciences (HURA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

TuHURA Biosciences generated $0 in revenue in fiscal year 2024.

EBITDA

N/A

Free Cash Flow

-$14.8M

YoY-22.9%

TuHURA Biosciences generated -$14.8M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 22.9% from the prior year.

Net Income

-$21.7M

YoY+26.0%

TuHURA Biosciences reported -$21.7M in net income in fiscal year 2024. This represents an increase of 26.0% from the prior year.

EPS (Diluted)

$-1.21

TuHURA Biosciences earned $-1.21 per diluted share (EPS) in fiscal year 2024. This represents an increase of 51.0% from the prior year.

Cash & Debt

$12.7M

YoY+245.3%

5Y CAGR+27.8%

10Y CAGR+10.3%

TuHURA Biosciences held $12.7M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

42M

TuHURA Biosciences had 42M shares outstanding in fiscal year 2024. This represents a decrease of 99.9% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$13.3M

YoY+41.8%

5Y CAGR+29.5%

TuHURA Biosciences invested $13.3M in research and development in fiscal year 2024. This represents an increase of 41.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$58K

YoY-26.9%

TuHURA Biosciences invested $58K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 26.9% from the prior year.

HURA Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$0	$0	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$13.3M+41.8%	$9.4M-38.0%	$15.2M+28.4%	$11.8M+225.5%	$3.6M-0.9%	$3.7M
SG&A Expenses	$4.3M+4.1%	$4.1M-44.8%	$7.5M-23.0%	$9.8M+116.1%	$4.5M-4.7%	$4.7M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$4.1M+22044.2%	$19K	N/A	$30K	N/A	N/A
Income Tax	$4K	$0	N/A	N/A	N/A	N/A
Net Income	-$21.7M+26.0%	-$29.3M-29.4%	-$22.7M+40.8%	-$38.3M-319.7%	-$9.1M-13.4%	-$8.0M
EPS (Diluted)	$-1.21	$-2.47	N/A	N/A	N/A	N/A

Metric	Q3'25	Q1'25	Q3'24	Q1'24	Q2'23	Q1'23	Q3'23	Q2'22
Revenue	N/A	$0	N/A	$0	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$5.0M+8.4%	$4.6M+55.5%	$2.9M-17.9%	$3.6M+3133.3%	$111K-94.0%	$1.9M-7.3%	$2.0M-2.6%	$2.1M
SG&A Expenses	$1.8M-27.7%	$2.4M+210.8%	$783K-22.9%	$1.0M+12.0%	$908K-17.7%	$1.1M-15.0%	$1.3M-9.9%	$1.4M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$17K	N/A	$2.0M+685.1%	$255K	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$7.1M-6.6%	-$6.7M-19.5%	-$5.6M-15.2%	-$4.8M-373.3%	-$1.0M+65.5%	-$3.0M+9.3%	-$3.3M+5.5%	-$3.5M
EPS (Diluted)	$-0.14+6.7%	$-0.15+72.2%	$-0.54	$-0.40	N/A	N/A	N/A	N/A

HURA Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$20.0M+357.8%	$4.4M-72.6%	$15.9M+17.8%	$13.5M+361.0%	$2.9M-27.2%	$4.0M
Current Assets	$19.6M+371.5%	$4.2M-68.6%	$13.3M+12.4%	$11.8M+313.6%	$2.9M-29.2%	$4.0M
Cash & Equivalents	$12.7M+245.3%	$3.7M-68.9%	$11.8M+11.8%	$10.5M+340.5%	$2.4M-35.7%	$3.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.4M-9.3%	$5.9M+42.6%	$4.2M+40.2%	$3.0M+10.7%	$2.7M+29.2%	$2.1M
Current Liabilities	$5.3M+48.2%	$3.6M-9.9%	$4.0M+43.5%	$2.8M+3.9%	$2.7M+29.2%	$2.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$14.6M+1036.3%	-$1.6M-113.2%	$11.8M+11.5%	$10.6M+3923.2%	$263K-86.6%	$2.0M
Retained Earnings	-$111.1M-25.6%	-$88.5M+35.1%	-$136.4M-22.6%	-$111.2M-59.5%	-$69.7M-15.1%	-$60.6M

Metric	Q3'25	Q1'25	Q3'24	Q1'24	Q2'23	Q1'23	Q3'23	Q2'22
Total Assets	$25.7M+75.5%	$14.6M-26.7%	$20.0M+168.2%	$7.4M+70.7%	$4.4M+195.3%	$1.5M-78.1%	$6.7M-32.0%	$9.9M
Current Assets	$3.5M-75.5%	$14.3M-27.0%	$19.6M+190.3%	$6.8M+62.4%	$4.2M+431.1%	$783K-87.0%	$6.0M-34.5%	$9.2M
Cash & Equivalents	$2.7M-56.6%	$6.2M-50.9%	$12.7M+99.3%	$6.4M+73.3%	$3.7M+1596.8%	$216K-92.9%	$3.0M-37.5%	$4.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$13.6M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.9M+86.5%	$4.8M-11.0%	$5.4M-60.2%	$13.5M+128.2%	$5.9M+69.0%	$3.5M+18.6%	$3.0M+223.8%	-$2.4M
Current Liabilities	$8.8M+84.7%	$4.8M-10.3%	$5.3M+297.5%	$1.3M-62.7%	$3.6M+7.8%	$3.3M+19.6%	$2.8M-13.9%	$3.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$16.8M+70.2%	$9.9M-32.5%	$14.6M+340.6%	-$6.1M-289.2%	-$1.6M+23.1%	-$2.0M-153.5%	$3.8M-69.2%	$12.3M
Retained Earnings	-$134.4M-14.1%	-$117.8M-6.0%	-$111.1M+29.5%	-$157.6M-78.1%	-$88.5M+42.7%	-$154.5M-4.4%	-$148.0M-2.3%	-$144.8M

HURA Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$14.7M-23.2%	-$12.0M+41.4%	-$20.4M-8.1%	-$18.9M-137.9%	-$7.9M-25.3%	-$6.3M
Capital Expenditures	$58K-26.9%	$79K-56.0%	$180K	N/A	N/A	N/A
Free Cash Flow	-$14.8M-22.9%	-$12.0M+41.5%	-$20.6M	N/A	N/A	N/A
Investing Cash Flow	-$6.1M-366.7%	-$1.3M	N/A	$964K	N/A	N/A
Financing Cash Flow	$29.8M+1019.2%	$2.7M-87.7%	$21.6M-16.9%	$26.0M+294.5%	$6.6M+62.0%	$4.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$25K	N/A	N/A	N/A	N/A

Metric	Q3'25	Q1'25	Q3'24	Q1'24	Q2'23	Q1'23	Q3'23	Q2'22
Operating Cash Flow	-$11.1M-134.0%	-$4.7M-82.3%	-$2.6M+32.2%	-$3.8M-81.1%	-$2.1M-60.7%	-$1.3M+27.9%	-$1.8M+15.5%	-$2.2M
Capital Expenditures	$0-100.0%	$43K+99.3%	$21K	N/A	N/A	N/A	$0	$0
Free Cash Flow	-$11.1M-131.9%	-$4.8M-82.4%	-$2.6M	N/A	N/A	N/A	-$1.8M+15.5%	-$2.2M
Investing Cash Flow	$0+100.0%	-$1.2M-39.8%	-$824K	$0	N/A	N/A	$0	$0
Financing Cash Flow	$5.3M+1062.1%	-$548K+84.4%	-$3.5M-175.9%	$4.6M+79.6%	$2.6M+129050.0%	-$2K0.0%	-$2K+96.0%	-$50K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

HURA Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-108.6%+563.5pp	-672.1%-530.0pp	-142.1%+140.7pp	-282.8%+27.8pp	-310.6%-111.3pp	-199.3%
Current Ratio	3.68+2.5	1.16-2.2	3.32-0.9	4.24+3.2	1.07-0.9	1.94
Debt-to-Equity	0.37+4.2	-3.80-4.2	0.35+0.1	0.28-9.9	10.17+9.1	1.05
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q1'25	Q3'24	Q1'24	Q2'23	Q1'23	Q3'23	Q2'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-27.6%+17.9pp	-45.5%+89.2pp	-134.8%-69.7pp	-65.0%-41.6pp	-23.4%+177.1pp	-200.5%-152.1pp	-48.4%-13.6pp	-34.8%
Current Ratio	0.40-2.6	3.00-0.7	3.68-1.4	5.04+3.9	1.16+0.9	0.23-1.9	2.16-0.7	2.83
Debt-to-Equity	0.53+0.0	0.49+0.1	0.37+2.6	-2.23+1.6	-3.80-2.1	-1.73-2.5	0.78+1.0	-0.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Io Biotech, Inc. IOBT

$26.6M

Oncolytics Biotech Inc ONCY

$114.1M

Pyxis Oncology, Inc. PYXS

$80.9M

Avalo Therapeutics Inc AVTX

$264.0M

Skye Bioscience SKYE

$23.2M

Frequently Asked Questions

What is TuHURA Biosciences's annual revenue?

TuHURA Biosciences (HURA) reported $0 in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is TuHURA Biosciences profitable?

No, TuHURA Biosciences (HURA) reported a net income of -$21.7M in fiscal year 2024.

What is TuHURA Biosciences's earnings per share (EPS)?

TuHURA Biosciences (HURA) reported diluted earnings per share of $-1.21 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is TuHURA Biosciences's free cash flow?

TuHURA Biosciences (HURA) generated -$14.8M in free cash flow during fiscal year 2024. This represents a -22.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is TuHURA Biosciences's operating cash flow?

TuHURA Biosciences (HURA) generated -$14.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are TuHURA Biosciences's total assets?

TuHURA Biosciences (HURA) had $20.0M in total assets as of fiscal year 2024, including both current and long-term assets.

What are TuHURA Biosciences's capital expenditures?

TuHURA Biosciences (HURA) invested $58K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does TuHURA Biosciences spend on research and development?

TuHURA Biosciences (HURA) invested $13.3M in research and development during fiscal year 2024.

How many shares does TuHURA Biosciences have outstanding?

TuHURA Biosciences (HURA) had 42M shares outstanding as of fiscal year 2024.

What is TuHURA Biosciences's current ratio?

TuHURA Biosciences (HURA) had a current ratio of 3.68 as of fiscal year 2024, which is generally considered healthy.

What is TuHURA Biosciences's debt-to-equity ratio?

TuHURA Biosciences (HURA) had a debt-to-equity ratio of 0.37 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is TuHURA Biosciences's return on assets (ROA)?

TuHURA Biosciences (HURA) had a return on assets of -108.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is TuHURA Biosciences's cash runway?

Based on fiscal year 2024 data, TuHURA Biosciences (HURA) had $12.7M in cash against an annual operating cash burn of $14.7M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is TuHURA Biosciences's Piotroski F-Score?

TuHURA Biosciences (HURA) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are TuHURA Biosciences's earnings high quality?

TuHURA Biosciences (HURA) has an earnings quality ratio of 0.68x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.